Kaleo, Inc.
Glen Allen, VA Doing business as Kaleo Inc.
- UEI
- LBM4GLJNDK31
- CAGE
- 5LVP8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 10900 Nuckols Rd #200, Glen Allen, VA 23060, USA
- Website
- kaleo.com
- Founded
- 2005
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory… | Office of the Assistant Secretary for Preparedness and Response | $96,058,494 | |
| Development of a novel pralidoxime chloride auto-injector device | Office of the Assistant Secretary for Preparedness and Response | $33,258,615 | |
| Funding received to purchase epinephrine auto-injectors for the national stockpile | Office of the Assistant Secretary for Preparedness and Response | $4,500,000 | |
| Refill of pharm items to meet cmops needs | Veterans Integrated Service Network 15 | $6,500 | |
| Naloxone injectors | Veterans Integrated Service Network 15 | $6,500 |
About Kaleo, Inc.
Kaleo, Inc. is a pharmaceutical company specializing in innovative auto-injector technologies for life-saving medications. Registered with SAM.gov since 2009, Kaleo has established itself as a key supplier of critical medical countermeasures and emergency response products to various federal agencies. The company primarily provides auto-injector devices for medications such as epinephrine, naloxone, and pralidoxime chloride, which are crucial for addressing public health emergencies, including the opioid crisis and chemical/biological defense requirements. Kaleo's expertise in developing and manufacturing these specialized medical devices has positioned it as an important partner in national preparedness efforts.
Kaleo's federal contract awards demonstrate its significant role in supplying essential medical products to government agencies. The company has received multiple prime contract awards from civilian agencies, particularly the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). Notable awards include a $27.1 million cost-plus-fixed-fee contract for the development of a novel pralidoxime chloride auto-injector device, supporting ASPR's Biomedical Advanced Research and Development Authority (BARDA) program. Additionally, Kaleo was awarded a $4.5 million definitive contract to supply epinephrine auto-injectors for the Strategic National Stockpile in response to the COVID-19 pandemic. The company has also fulfilled smaller orders for the Department of Veterans Affairs, providing naloxone injectors and other pharmaceutical items. These contracts highlight Kaleo's capacity to deliver both large-scale development projects and immediate supply needs for critical medications.
Kaleo holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that facilitate ongoing procurement of its products. The company has a $39.7 million Other Transaction IDV with the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense for auto-injector devices and services. Another major IDV is a $74.3 million agreement for naloxone auto-injector production, also with the Army. The Department of Veterans Affairs has awarded Kaleo multiple IDVs, including a $225,000 Federal Supply Schedule contract for drugs and pharmaceuticals, and a $5,025 single-award Blanket Purchase Agreement for naloxone delivery. These IDVs span various contract types, including Other Transaction Agreements, Federal Supply Schedules, and Blanket Purchase Agreements, demonstrating Kaleo's versatility in meeting federal procurement requirements. The range of agencies utilizing these IDVs, from defense to veterans' affairs, underscores the broad applicability and critical nature of Kaleo's auto-injector products across different sectors of the federal government.
Contract vehicles
SBA capabilities narrative
Kaleo is a new type of pharmaceutical company, dedicated to building innovative solutions for serious and life-threatening medical conditions. We believe patients and caregivers are the experts on how their medical condition impacts their lives and are an integral part of our product development process.
Quick answers
What is Kaleo, Inc.'s UEI?
Kaleo, Inc.'s Unique Entity ID (UEI) in SAM.gov is LBM4GLJNDK31.
What is Kaleo, Inc.'s CAGE code?
Kaleo, Inc.'s CAGE code is 5LVP8.
What is Kaleo, Inc.'s primary NAICS code?
Kaleo, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Kaleo, Inc. located?
Kaleo, Inc.'s physical address in SAM.gov is 10900 Nuckols Rd #200, Glen Allen, VA 23060, USA.
Is Kaleo, Inc. registered in SAM.gov?
Yes. Kaleo, Inc.'s SAM.gov registration is active through July 23, 2027.
Which contract vehicles does Kaleo, Inc. hold?
Kaleo, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Kaleo, Inc.'s most recent federal award?
Kaleo, Inc.'s most recent federal contract award is This acquisition will allow barda to invest project bioshield funds for late-stage clinical development, regulatory… (75A50126C00010), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2026.
On GovTribe
See Kaleo, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors